Olink

Olink®
Part of Thermo Fisher Scientific

Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2pos subjects

Cell Research, 2021

Yu S., Di C., Chen S., Guo M., Yan J., Zhu Z., Liu L., Feng R., Xie Y., Zhang R., Chen J., Wang M., Wei D., Fang H., Yin T., Huang J., Chen S., Lu H., Zhu J., Qu J.

Disease areaApplication areaSample typeProducts
Infectious Diseases
Pathophysiology
Plasma
Olink Target 96

Olink Target 96

Abstract

Increasing numbers of SARS-CoV-2-positive (SARS-CoV-2pos) subjects are detected at silent SARS-CoV-2 infection stage (SSIS). Yet, SSIS represents a poorly examined time-window wherein unknown immunity patterns may contribute to the fate determination towards persistently asymptomatic or overt disease. Here, we retrieved blood samples from 19 asymptomatic and 12 presymptomatic SARS-CoV-2pos subjects, 47 age/gender-matched patients with mild or moderate COVID-19 and 27 normal subjects, and interrogated them with combined assays of 44-plex CyTOF, RNA-seq and Olink. Notably, both asymptomatic and presymptomatic subjects exhibited numerous readily detectable immunological alterations, while certain parameters including more severely decreased frequencies of CD107alow classical monocytes, intermediate monocytes, non-classical monocytes and CD62Lhi CD8+ Tnaïve cells, reduced plasma STC1 level but an increased frequency of CD4+ NKT cells combined to distinguish the latter. Intercorrelation analyses revealed a particular presymptomatic immunotype mainly manifesting as monocytic overactivation and differentiation blockage, a likely lymphocyte exhaustion and immunosuppression, yielding mechanistic insights into SSIS fate determination, which could potentially improve SARS-CoV-2 management.

Read publication ↗